NZ528624A - Antibodies against cancer - Google Patents

Antibodies against cancer

Info

Publication number
NZ528624A
NZ528624A NZ528624A NZ52862402A NZ528624A NZ 528624 A NZ528624 A NZ 528624A NZ 528624 A NZ528624 A NZ 528624A NZ 52862402 A NZ52862402 A NZ 52862402A NZ 528624 A NZ528624 A NZ 528624A
Authority
NZ
New Zealand
Prior art keywords
antibody
cancer
fragment
monoclonal
antibodies against
Prior art date
Application number
NZ528624A
Other languages
English (en)
Inventor
Ian Farquar Campbell Mckenzie
Pei-Xiang Xing
Original Assignee
Austin Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Austin Research Inst filed Critical Austin Research Inst
Publication of NZ528624A publication Critical patent/NZ528624A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ528624A 2001-03-26 2002-03-26 Antibodies against cancer NZ528624A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR3958A AUPR395801A0 (en) 2001-03-26 2001-03-26 Antibodies against cancer
PCT/AU2002/000362 WO2002077033A1 (en) 2001-03-26 2002-03-26 Antibodies against cancer

Publications (1)

Publication Number Publication Date
NZ528624A true NZ528624A (en) 2006-03-31

Family

ID=3827964

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ528624A NZ528624A (en) 2001-03-26 2002-03-26 Antibodies against cancer

Country Status (9)

Country Link
US (1) US7318924B2 (cg-RX-API-DMAC7.html)
EP (1) EP1383801A4 (cg-RX-API-DMAC7.html)
JP (2) JP4854912B2 (cg-RX-API-DMAC7.html)
KR (1) KR100909290B1 (cg-RX-API-DMAC7.html)
CN (2) CN100457781C (cg-RX-API-DMAC7.html)
AU (3) AUPR395801A0 (cg-RX-API-DMAC7.html)
CA (1) CA2442318A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ528624A (cg-RX-API-DMAC7.html)
WO (1) WO2002077033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
CA2443840C (en) 2001-04-26 2010-10-26 Biogen, Inc. Cripto blocking antibodies and uses thereof
WO2004037990A2 (en) * 2002-10-23 2004-05-06 Exelixis, Inc. MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
EP1624073A4 (en) * 2003-04-03 2006-05-17 Oncorex Inc DRUG
AU2004252170B2 (en) * 2003-06-27 2011-01-27 Biogen Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP2135952A3 (en) 2003-09-15 2010-09-29 Research Development Foundation Cripto antagonism of activin and TGF-beta signaling
CA2542332C (en) 2003-10-16 2013-03-12 Stephen John Ralph Immunomodulating compositions and uses therefor
KR20070100346A (ko) * 2005-01-05 2007-10-10 바이오겐 아이덱 엠에이 인코포레이티드 크립토 결합 분자
US7939056B2 (en) * 2005-11-14 2011-05-10 The Brigham And Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
CN101970001A (zh) * 2007-06-01 2011-02-09 比奥根艾迪克Ma公司 Cripto结合分子
EP3766517B1 (en) 2008-06-20 2022-11-02 Duke University Compositions, methods, and kits for eliciting an immune response
KR100973029B1 (ko) * 2008-10-07 2010-08-11 박지운 알루미늄 합금 가로등 등주
WO2010054328A2 (en) * 2008-11-07 2010-05-14 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
JP5990752B2 (ja) * 2011-01-31 2016-09-14 オリンパス株式会社 抗体療法の効果増強剤
CN103826661B (zh) 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途
JP6721507B2 (ja) 2013-12-23 2020-07-15 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ）
KR102739664B1 (ko) * 2015-04-20 2024-12-05 미노믹 인터내셔널 리미티드 치료용 항체 및 이의 용도
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
HK1246717A1 (zh) 2015-06-23 2018-09-14 Bayer Pharma Aktiengesellschaft Ksp抑制剂的靶向缀合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MX2018011627A (es) 2016-03-24 2019-01-10 Bayer Pharma AG Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles.
EP3471776B1 (en) 2016-06-15 2022-05-04 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies
KR102583006B1 (ko) 2016-12-21 2023-09-27 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
KR20190099250A (ko) 2016-12-21 2019-08-26 바이엘 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
CN109744199A (zh) * 2017-11-08 2019-05-14 南京艾莫瑞生物科技有限公司 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用
JP6761889B1 (ja) * 2019-11-11 2020-09-30 株式会社Ｇｓｐエンタープライズ 抗ヒトＣｒｉｐｔｏ−１抗体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US5256643A (en) * 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5264557A (en) 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
KR20000015893A (ko) 1996-05-22 2000-03-15 댄 마이클 특이적으로 암세포를 검출하는 항원 결합 단편, 상기 단편을 코딩하는 뉴클레오티드 및 암의 예방 및 검출에 사용되는 이들의 용도
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
AU766256B2 (en) 1999-03-11 2003-10-09 Ardenia Investments Ltd. New compounds for the treatment of cancer
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
JP2004524810A (ja) 2000-09-18 2004-08-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏ変異体およびその使用
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
CA2443840C (en) 2001-04-26 2010-10-26 Biogen, Inc. Cripto blocking antibodies and uses thereof

Also Published As

Publication number Publication date
JP4854912B2 (ja) 2012-01-18
AUPR395801A0 (en) 2001-04-26
US7318924B2 (en) 2008-01-15
WO2002077033A1 (en) 2002-10-03
AU2002240719B2 (en) 2007-01-11
CN1639194A (zh) 2005-07-13
JP2009024014A (ja) 2009-02-05
EP1383801A4 (en) 2005-06-01
CN101310770A (zh) 2008-11-26
KR20040010613A (ko) 2004-01-31
EP1383801A1 (en) 2004-01-28
KR100909290B1 (ko) 2009-07-24
JP2004534741A (ja) 2004-11-18
CN100457781C (zh) 2009-02-04
AU2007201587A1 (en) 2007-05-03
CA2442318A1 (en) 2002-10-03
US20040176576A1 (en) 2004-09-09

Similar Documents

Publication Publication Date Title
NZ528624A (en) Antibodies against cancer
RU2008128244A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
IL161686A (en) Use of a soluble monoclonal antibody that specifically binds trail receptor dr5 in the manufacture of pharmaceutical compositions targeting cells expressing dr5
JP2003503361A5 (cg-RX-API-DMAC7.html)
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2004032857A3 (en) Antibody therapy
JP2004534741A5 (cg-RX-API-DMAC7.html)
WO2004010947A3 (en) Humanized antibodies against human 4-1bb
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
ZA200609407B (en) Monoclonal antibodies to hepatocyte growth factor
NZ568769A (en) Human monoclonal antibodies against CD20
NZ572756A (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
NZ596878A (en) Methods of administering anti-tnfalpha antibodies
CA2383493A1 (en) Treating prostate cancer with anti-erbb2 antibodies
WO2003099196A3 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
TR200102845T2 (tr) Kanserlerin iyileştirilmesi için RHUMAB HER2 ile birlikte dosetaksel
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
TW200517124A (en) Fully human antibodies against human 4-1BB
SI1684770T1 (sl) Oligo-beta-(1,3)-glukan in monoklonska protitelesa proti raku
WO2024062072A3 (en) Anti-ccr8 monoclonal antibodies and their therapeutic use
EP2641611A3 (en) Combination therapy
WO2002072008A3 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed